Nasdaq Biotech Index
Pioneer the Possible
With disruption in our DNA, we are home to today’s top and emerging biotech companies, helping them pioneer a better tomorrow.
The Benchmark for Technology-Driven Healthcare Innovation
BioTechnology Index
With its rules-based, transparent index methodology utilizing modified market cap-weighting, the Nasdaq Biotechnology Index (NBI) reflects the dynamic, innovation-driven world of Nasdaq-listed biotech companies. NBI captures hundreds of constituents of various sizes, while ensuring that the largest, most important players in the space are weighted appropriately.
Index Charts & Data
Top 10 Index Weights as of December 31, 2021 (%)
Top 10 Index Weights: FY'21 vs. FY'20 Returns (%)
Investing in Biotech with Nasdaq Index
Invesco Nasdaq Biotechnology ETF
Biotech is paving the way for a post-pandemic world. Through the Invesco Nasdaq Biotechnology ETF, access a high concentration of companies critical to COVID-19 vaccines and treatments, as well as the continued growth of genomics, wellness and advanced medical therapeutics.
ETPs Tracking NBI
Given the strength of the Nasdaq Biotech Index, numerous exchange-traded products are tracking the index. From Asia to North America and Europe to the Middle East, discover the global reach of NBI.
"We are excited to expand our relationship with Nasdaq in order to offer investors another way to access innovative companies currently shaping the way we live and work."
Nasdaq Biotech Index on TradeTalks
/
7
Pillars of Possibilities
Home to 600+ Biotech Companies
Backing BioTech Since the Beginning
We've backed biotech for 50 years and counting, providing the disruptors and innovators with a place to call home and access to the capital they need to propel their businesses forward. 98% of U.S. Listed Biotech Companies are listed on Nasdaq.
Quarter of a Century
Benchmarking Innovation
The Nasdaq Biotech Index has provided a benchmark for biotech innovation for more than 25 years.
"We are the home to Biotech because we committed to the industry from the very beginning. Our gateway to the capital markets allows researchers, scientists and business leaders to pioneer the possible every day—and we are proud to be with them at every step of that journey."
NBI in the News
Nasdaq: MRNA
Moderna Announces FDA Authorization of Its COVID-19 Vaccine in U.S.
In December 2020, Moderna COVID-19 Vaccine was authorized for distribution and use under an Emergency Use Authorization (EUA). Delivery to the U.S. Government began immediately.
Nasdaq: AMGN
Amgen Wins Approval for Pathbreaking Lung Cancer Drugs
A potential blockbuster, this new drug is first to treat common cancer mutation called KRAS that researchers struggled for years to target.
Nasdaq: BNTX
BioNTech to roll out mRNA Production in Africa
Pharmaceutical company BioNTech has announced plans to establish mRNA vaccine production facilities in Africa — part of a larger plan to combat diseases on the continent.
Global Index Resources
Contact Us
What's Next For the Innovators of the Nasdaq Biotechnology Index?
Biotech's Post-Covid Future
Learn what drove biotech performance in the pivotal year of 2021, and why having the proper benchmark for this unique industry is more important than ever. Along with a special guest from Nasdaq-listed BioMarin Pharmaceutical, take a deep dive into some of the cutting-edge innovation happening within the space, especially as it relates to gene therapy for the treatment of rare diseases.
More Webinars & Resources
-
- 2021 Year in Review: What’s New with the Innovators of the Nasdaq Biotechnology Index?
- Invesco and Nasdaq Expand Partnership with Two New Thematic ETFs
- Nasdaq Biotech Index: A True Benchmark for Technology-Driven Healthcare Innovation
- Biotech in the Age of Coronavirus
- Deals and Data are the Heartbeat of Biotech
- The True Benchmark for Tech-Driven Innovation in Healthcare [WEBINAR]